ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience

BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sang Hyoung, Kim, Shin, Ko, Ok Bae, Koo, Ja Eun, Lee, Danbi, Jeong, Yong Pil, Huh, Jooryung, Kim, Sung-Bae, Kim, Sang We, Lee, Jae-Lyun, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2006
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890718/
https://www.ncbi.nlm.nih.gov/pubmed/17017664
http://dx.doi.org/10.3904/kjim.2006.21.3.159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890718/
https://www.ncbi.nlm.nih.gov/pubmed/17017664
http://dx.doi.org/10.3904/kjim.2006.21.3.159

Ejemplares similares